Arrowstreet Capital, Limited Partnership Alkermes Plc. Transaction History

Arrowstreet Capital, Limited Partnership

$121 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$26.4 - $32.56 $774,364 - $955,049	-29,332 Reduced 17.94%	134,181 $3.63 Million
Q4 2023 Feb 14, 2024	SELL	$23.37 - $28.68 $19.4 Million - $23.9 Million	-831,714 Reduced 83.57%	163,513 $4.54 Million
Q3 2023 Nov 14, 2023	BUY	$27.17 - $31.97 $6.49 Million - $7.64 Million	238,826 Added 31.57%	995,227 $27.9 Million
Q2 2023 Aug 14, 2023	BUY	$28.34 - $33.63 $2.22 Million - $2.64 Million	78,467 Added 11.57%	756,401 $23.7 Million
Q1 2023 May 15, 2023	SELL	$25.31 - $29.02 $14.5 Million - $16.7 Million	-574,701 Reduced 45.88%	677,934 $19.1 Million
Q4 2022 Feb 14, 2023	BUY	$21.94 - $26.24 $8.01 Million - $9.57 Million	364,896 Added 41.1%	1,252,635 $32.7 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $5.23 Million - $7.57 Million	237,520 Added 36.53%	887,739 $19.8 Million
Q2 2022 Aug 15, 2022	SELL	$26.4 - $30.54 $39.5 Million - $45.7 Million	-1,497,018 Reduced 69.72%	650,219 $19.4 Million
Q1 2022 May 13, 2022	BUY	$23.07 - $27.99 $49.5 Million - $60.1 Million	2,147,237 New	2,147,237 $56.5 Million
Q3 2021 Nov 12, 2021	SELL	$23.37 - $32.13 $36.1 Million - $49.6 Million	-1,542,778 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$18.78 - $25.15 $6.44 Million - $8.63 Million	343,111 Added 28.6%	1,542,778 $37.8 Million
Q1 2021 May 14, 2021	SELL	$18.21 - $23.2 $16.1 Million - $20.5 Million	-882,934 Reduced 42.4%	1,199,667 $22.4 Million
Q4 2020 Feb 12, 2021	BUY	$15.39 - $22.1 $158,517 - $227,630	10,300 Added 0.5%	2,082,601 $41.5 Million
Q3 2020 Nov 12, 2020	BUY	$16.16 - $20.66 $7.2 Million - $9.2 Million	445,443 Added 27.38%	2,072,301 $34.3 Million
Q2 2020 Aug 12, 2020	BUY	$13.31 - $19.41 $952,703 - $1.39 Million	71,578 Added 4.6%	1,626,858 $31.6 Million
Q1 2020 May 15, 2020	SELL	$13.06 - $21.24 $8.62 Million - $14 Million	-660,307 Reduced 29.8%	1,555,280 $22.4 Million
Q4 2019 Feb 13, 2020	BUY	$17.29 - $21.74 $38.3 Million - $48.2 Million	2,215,587 New	2,215,587 $45.2 Million
Q3 2019 Nov 14, 2019	SELL	$19.51 - $24.28 $3.64 Million - $4.53 Million	-186,556 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$21.47 - $37.33 $6.2 Million - $10.8 Million	-288,552 Reduced 60.73%	186,556 $4.21 Million
Q1 2019 May 15, 2019	BUY	$28.4 - $36.49 $7.55 Million - $9.7 Million	265,831 Added 127.02%	475,108 $17.3 Million
Q4 2018 Feb 14, 2019	BUY	$27.94 - $44.61 $5.85 Million - $9.34 Million	209,277 New	209,277 $6.18 Million

Others Institutions Holding ALKS

# of Institutions

362

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

Black Rock Inc. New York, NY

29.1M
Shares

$863 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

19M
Shares

$563 Million
0.01% of portfolio
Price T Rowe Associates Inc Baltimore, MD

13M
Shares

$385 Million
0.04% of portfolio
Wellington Management Group LLP Boston, MA

12.7M
Shares

$375 Million
0.06% of portfolio
State Street Corp Boston, MA

9.19M
Shares

$272 Million
0.01% of portfolio

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.87B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.

Account